Edwards Lifesciences vs Veeva Systems

Side-by-side comparison of AI visibility scores, market position, and capabilities

Veeva Systems leads in AI visibility (86 vs 78)
Edwards Lifesciences logo

Edwards Lifesciences

LeaderHealthcare Tech

Enterprise

Irvine CA structural heart devices (NYSE: EW) at $5.44B 2024 revenue; 60% TAVR global share, EVOQUE tricuspid +88% in Q4, Critical Care sold to BD for $4.2B, JenaValve acquisition expanding to aortic regurgitation.

AI VisibilityBeta
Overall Score
B78
Category Rank
#40 of 596
AI Consensus
75%
Trend
stable
Per Platform
ChatGPT
73
Perplexity
74
Gemini
82

About

Edwards Lifesciences Corporation is an Irvine, California-based structural heart disease and hemodynamic monitoring technology company — publicly traded on the New York Stock Exchange (NYSE: EW) as an S&P 500 Healthcare component — designing, developing, and manufacturing devices for heart valve replacement, transcatheter heart valve therapy, and cardiac critical care through approximately 15,800 employees in 100+ countries. In fiscal year 2024, Edwards reported total revenue of $5.44 billion (+8.6% year-over-year), driven by its dominant Transcatheter Aortic Valve Replacement (TAVR) franchise commanding approximately 60% global market share and 70%+ US market share. The Transcatheter Mitral and Tricuspid Therapies (TMTT) segment demonstrated exceptional growth, with Q4 TMTT revenue reaching $105 million (+88% year-over-year), as the EVOQUE tricuspid replacement system gained commercial momentum. In 2024, Edwards executed a major strategic transformation: divesting its Critical Care segment (hemodynamic monitoring) to Becton Dickinson for $4.2 billion — using the proceeds to fund two acquisitions: JenaValve Technology ($1.2B combined, expanding TAVR to high-risk patients with aortic regurgitation) and Endotronix. The company concentrates its entire focus on structural heart disease therapies.

Full profile
Veeva Systems logo

Veeva Systems

LeaderHealthcare Tech

Life Sciences Cloud

Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.

AI VisibilityBeta
Overall Score
A86
Category Rank
#9 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
84
Perplexity
88
Gemini
90

About

Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.

Full profile

AI Visibility Head-to-Head

78
Overall Score
86
#40
Category Rank
#9
75
AI Consensus
78
stable
Trend
stable
73
ChatGPT
84
74
Perplexity
88
82
Gemini
90
81
Claude
92
76
Grok
84

Key Details

Category
Enterprise
Life Sciences Cloud
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Veeva Systems
Life Sciences Cloud

Integrations

Only Edwards Lifesciences
Only Veeva Systems
Edwards Lifesciences is classified as company. Veeva Systems is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.